reports
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’
Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’ Den nye 5-årige strategi, Impact4, vil blive lanceret i dag på selskabets Capital Markets Day 2025. Strategien Impact4 sætter kunden i centrum og udstikker samtidig et ambitiøst mål for selskabet – at hjælpe 4 millioner mennesker på lang sigt. Med Impact4 fokuserer vi på fire strategiske prioriteter, der er afgørende for vores succes og værdiskabelse: ’Grow through innovative customer offerings’ ved at sætte standarden for sundhedspleje og ved at skabe et stærkt fokus på kunderne på tværs af alle vores forretningsområder.’Unl...
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4 The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With Impact4, we focus on four strategic priorities which are essential to our success and value creation: Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity across all our business areas.Unlock next level e...
Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye fi...
Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye finansielle forventninger frem mod 2030 I forbindelse med lanceringen af Coloplasts nye 5-årige strategi, Impact4, offentliggør virksomheden en ny finansiel ambition med en organisk omsætningsvækst på 7-8 % (5-årige CAGR) frem til regnskabsåret 2029/30, en vækst i absolut EBIT* på niveau med eller over omsætningsvæksten i perioden og et afkast af investeret kapital (ROIC) på mere end 20 % i regnskabsåret 2029/30. På sin Capital Markets Day den 2. september 2025 vil Coloplast præsentere en ny 5-årig strategi, Impact4. I fo...
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new fin...
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030 In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30. At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy, Impact4. In relation to the strategic update, Coloplast is providing a new long-te...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S – Updated presenters list for Capital Markets Day on 2 S...
Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025 Following the changes to the Executive Leadership Team, announced on 19.08.2025*, we are pleased to share with you the updated presenters list for our Capital Markets Day on 2 September 2025. For those of you who have signed up, we look forward to seeing you at the event. The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) The event will be held in person at Clarion Hotel in Copenh...
- Maxime Kogge
- Maxime Kogge
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Regnskabsmeddelelse, 9M 2024/25
Coloplast A/S - Regnskabsmeddelelse, 9M 2024/25 2024/25 Delårsrapport, 9M 2024/25 1. oktober 2024 - 30. juni 2025 Coloplast leverede en organisk vækst på 7% og en overskudsgrad1 på 28% i 3. kvartal. Den rapporterede omsætning i danske kroner steg 1%, negativt påvirket af valutaudviklingen samt frasalget af hudplejeforretningen. Den organiske vækst pr. forretningsområde: Stomi 6%, Kontinens 8%, Stemme og Respiratorisk Pleje 9%, Avanceret Sårpleje 4% og Urologi 4%.Væksten i Stomi var drevet af et bredt baseret bidrag fra alle regioner, bortset fra Kina, som leverede en lav-encifret v...
Coloplast A/S - Interim Financial Report, 9M 2024/25
Coloplast A/S - Interim Financial Report, 9M 2024/25 2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%.Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit gro...
Coloplast A/S - Selskabsmeddelelse nr. 05/2025 - Coloplast ændrer i le...
Coloplast A/S - Selskabsmeddelelse nr. 05/2025 - Coloplast ændrer i ledelsesteamet Coloplast ændrer i ledelsesteamet Coloplasts bestyrelse laver ændringer til ledelsesteamet (ELT) for at understøtte en succesfuld eksekvering af ny strategi. I løbet af de seneste måneder har seniorledere fra hele Coloplast arbejdet sammen om at færdiggøre Coloplasts nye strategi, som vil blive lanceret internt og eksternt i begyndelsen af september efter bestyrelsens godkendelse. "Vores nye strategi er centreret omkring vores kunder. Vi vil skabe og levere den bedste kundeoplevelse for vores brugere, pati...
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes...
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to Executive Leadership Team Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, senior leaders from across the Coloplast Group have worked together to finalise the new Coloplast Group strategy, which will be communicated internally and externally in early September following approval by the Board of Directors. “Our new ...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference...
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST Tuesday, 19 August 2025 at 11.00 - 12.00h CESTIn connection with the publication of Coloplast’s interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available d...
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 Sep...
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025 The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets Day.The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session.The purpose of the event is to give institutional investors and financial analysts an introductio...
Coloplast AS: 1 director
A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.